Globus Medical, Inc. (FRA:GM0N)
Germany · Delayed Price · Currency is EUR | Market Cap | 9.54B +32.6% |
| Revenue (ttm) | 2.75B +19.7% |
| Net Income | 468.66M +50.1% |
| EPS | 3.42 +51.9% |
| Shares Out | n/a |
| PE Ratio | 20.37 |
| Forward PE | 15.84 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 70.22 |
| Previous Close | 70.64 |
| Day's Range | 70.22 - 70.22 |
| 52-Week Range | 46.60 - 83.50 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 6, 2026 |
About Globus Medical
Globus Medical, Inc. develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products comprising traditional fusion implants, such as pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices; treatment options for motion preservation technologies consisting of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractu... [Read more]
Financial Performance
In 2025, Globus Medical's revenue was $2.94 billion, an increase of 16.65% compared to the previous year's $2.52 billion. Earnings were $537.87 million, an increase of 422.28%.
Financial numbers in USD Financial StatementsNews
Globus Medical price target raised to $85 from $80 at Stifel
Stifel raised the firm’s price target on Globus Medical (GMED) to $85 from $80 and keeps a Hold rating on the shares.
Globus Medical price target lowered to $99 from $103 at Wells Fargo
Wells Fargo lowered the firm’s price target on Globus Medical (GMED) to $99 from $103 and keeps an Overweight rating on the shares. The firm notes Q2 EPS of $1.34…
Globus Medical sees Q3 revenue $67M-$73M, consensus $70.38M
At the midpoint of this outlook, the Company anticipates 30 percent year-over-year growth with approximately $40 million from the core business and $30 million from Wuxi indie Micro. Published first…
Globus Medical reports Q2 adjusted EPS $1.34, consensus $1.10
Reports Q2 revenue $789.61M, consensus $782.84M. “Momentum continued into the second quarter with 6% overall revenue growth, or 9% growth excluding Nevro, driven by share gains across a majority of…
Globus Medical updates FY adjusted EPS view to $4.95-$5.05 from $4.70-$4.80
Consensus is $4.74. Backs FY26 revenue view $3.18B-$3.22B, consensus $3.2B.
Globus Medical Earnings Call Transcript: Q2 2026
Q2 2026 delivered 6% revenue growth (9% excluding Nevro), record non-GAAP EPS, and 35.4% adjusted EBITDA margin. U.S. and international spine, trauma, and neuromonitoring drove strong results, while Enabling Technologies and Nevro remained soft. Full-year guidance was reaffirmed, with EPS guidance raised on margin expansion.
Globus Medical Earnings release: Q2 2026
Globus Medical released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Globus Medical Quarterly report: Q2 2026
Globus Medical has published its Q2 2026 quarterly earnings report on August 6, 2026.
Globus Medical Reports Second Quarter 2026 Results
AUDUBON, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced its financial results for the second quarter ended June...
Globus Medical initiated with a Neutral at UBS
UBS initiated coverage of Globus Medical (GMED) with a Neutral rating and $82 price target The firm sees modest spine market growth ahead, with surgeon and hospital feedback indicating low-single-digi...
Globus Medical initiated with a Neutral at UBS
UBS initiated coverage of Globus Medical (GMED) with a Neutral rating and $82 price target
Globus Medical Schedules Second Quarter Earnings Release and Conference Call
AUDUBON, Pa., July 16, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, will announce its financial results for the second quarter ended June 30...
Globus Medical price target lowered to $100 from $115 at Truist
Truist analyst Richard Newitter lowered the firm’s price target on Globus Medical (GMED) to $100 from $115 and keeps a Buy rating on the shares as part of a broader…
Globus Medical price target lowered to $115 from $120 at RBC Capital
RBC Capital analyst Shagun Singh lowered the firm’s price target on Globus Medical (GMED) to $115 from $120 and keeps an Outperform rating on the shares as part of a…
BMO Capital starts Globus Medical at Outperform on earnings power
As previously reported, BMO Capital initiated coverage of Globus Medical (GMED) with an Outperform rating and $94 price target The market continues to underappreciate the earnings power of the fully…
Globus Medical initiated with an Outperform at BMO Capital
BMO Capital initiated coverage of Globus Medical (GMED) with an Outperform rating and $94 price target
Globus Medical price target lowered to $80 from $95 at Stifel
Stifel analyst Thomas Stephan lowered the firm’s price target on Globus Medical (GMED) to $80 from $95 and keeps a Hold rating on the shares. 2026 revenue expectations are being…
Globus Medical price target lowered to $100 from $115 at Piper Sandler
Piper Sandler analyst Matt O’Brien lowered the firm’s price target on Globus Medical (GMED) to $100 from $115 and keeps an Overweight rating on the shares. The firm is updating…
Globus Medical price target raised to $117 from $114 at Needham
Needham raised the firm’s price target on Globus Medical (GMED) to $117 from $114 and keeps a Buy rating on the shares.
Globus Medical price target lowered to $103 from $104 at Wells Fargo
Wells Fargo analyst Larry Biegelsen lowered the firm’s price target on Globus Medical (GMED) to $103 from $104 and keeps an Overweight rating on the shares. The firm notes Globus…
Globus Medical reports Q1 EPS $1.12, consensus 92c
Reports Q1 revenue $759.85M, consensus $740.83M. “We’re off to a strong start in 2026 with 27% overall revenue growth and record first quarter earnings. Organic revenue grew over 13%, driven…
Globus Medical raises FY26 EPS view to $4.70-$4.80 from $4.40-$4.50
Consensus $4.47. Backs FY26 revenue view $3.18B-$3.22B, consensus $3.2B. The company said, “The Company reaffirms its guidance for full-year 2026 revenue to be in the range of $3.18 billion to…
Globus Medical Earnings Call Transcript: Q1 2026
Q1 2026 delivered 27% revenue growth and 64.7% non-GAAP EPS growth, driven by strong U.S. and international spine, trauma, and enabling technologies. Margin expansion and operational efficiency led to raised EPS guidance, while Nevro is expected to recover in H2 2026.
Globus Medical Earnings release: Q1 2026
Globus Medical released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Globus Medical Quarterly report: Q1 2026
Globus Medical has published its Q1 2026 quarterly earnings report on May 7, 2026.